Advanced search
Publication Cover
Journal of Medical Economics Volume 25, 2022 - Issue 1
Submit an article Journal homepage
1,399
Views
1
CrossRef citations to date
0
Altmetric
Oncology

Long-term hospital resource utilization and associated costs of care for patients initiating nivolumab in advanced non-small cell lung cancer in France

Valentine Grumberga Bristol Myers Squibb France, Rueil-Malmaison, France;b Oncostat, CESP, INSERM U1018, Paris-Saclay University, “Ligue Contre le Cancer” labeled team, Villejuif, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2424-6748
ORCID Icon,
Christos Chouaïdc Department of Chest Medicine, Créteil University Hospital, Créteil, France;d INSERM U955, UPEC, IMRB, Créteil, FranceORCID Iconhttps://orcid.org/0000-0002-4290-5524
ORCID Icon,
François-Emery Cottéa Bristol Myers Squibb France, Rueil-Malmaison, FranceORCID Iconhttps://orcid.org/0000-0002-6758-4552
ORCID Icon,
Baptiste Jouanetone HEVA, Lyon, FranceORCID Iconhttps://orcid.org/0000-0001-6764-4335
ORCID Icon,
Ronan Jolivele HEVA, Lyon, FranceORCID Iconhttps://orcid.org/0000-0001-6389-5372
ORCID Icon,
Anne-Françoise Gaudina Bristol Myers Squibb France, Rueil-Malmaison, FranceORCID Iconhttps://orcid.org/0000-0002-6946-2479
ORCID Icon,
Dorothée Reynauda Bristol Myers Squibb France, Rueil-Malmaison, FranceORCID Iconhttps://orcid.org/0000-0003-0534-5713
ORCID Icon,
Jean-Baptiste Assiéc Department of Chest Medicine, Créteil University Hospital, Créteil, France;f INSERM U1138 Centre de Recherche des Cordeliers (CRC), Paris, FranceORCID Iconhttps://orcid.org/0000-0002-9749-4937
ORCID Icon &
Isabelle Borgetb Oncostat, CESP, INSERM U1018, Paris-Saclay University, “Ligue Contre le Cancer” labeled team, Villejuif, France;g Biostatistics and Epidemiology Office, Direction of Clinical Research, Gustave Roussy, Paris-Saclay University, Villejuif, FranceORCID Iconhttps://orcid.org/0000-0002-6295-6361
ORCID Icon show all
Pages 691-699 | Received 24 Mar 2022, Accepted 16 May 2022, Published online: 30 May 2022

References

  • Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:691–387.
  • Haute Autorité de Santé. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2013-10/guide_k_bronchopulmonaires_finalweb__091013.pdf.
  • Chouaïd C, Debieuvre D, Durand-Zaleski I, et al. Survival inequalities in patients with lung cancer in France: a nationwide cohort study (the TERRITOIRE study). PLoS One. 2017;12(8):e0182798.
  • Borghaei H, Gettinger S, Vokes EE, et al. Five-Year outcomes from the randomized, phase III trials CheckMate 017 and 057: Nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39(7):723–733.
  • Caisse Nationale d’Assurance Maladie. Available from: https://assurance-maladie.ameli.fr/sites/default/files/rapport-charges-et-produits-2020.pdf.
  • Chouaïd C, Molinier L, Combescure C, et al. Economics of the clinical management of lung cancer in France: an analysis using a markov model. Br J Cancer. 2004;90(2):397–402.
  • Vergnenègre A, Carrato A, Thomas M, et al. Real-world healthcare resource utilization in a european non-small cell lung cancer population: the EPICLIN-Lung study. Curr Med Res Opin. 2014;30(3):463–470.
  • Lee DH, Isobe H, Wirtz H, et al. Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study. BMC Health Serv Res. 2018;18(1):147.
  • Tanguy-Melac A, Denis P, Pestel L, et al. Intensity of care, expenditure, place and cause of death people with lung cancer in the year before their death: a french population based study. Bull Cancer. 2020;107(3):308–321.
  • Huang Y, Diaby V. Pcn142 healthcare resource utilization analysis on immune checkpoint inhibitors in patients with metastatic lung cancer using claims database. Value in Health. 2020;23:S48.
  • Korytowsky B, Radtchenko J, Nwokeji ED, et al. Understanding total cost of care in advanced non-small cell lung cancer pre- and postapproval of immuno-oncology therapies. Am J Manag Care. 2018;24(20):439–43S. 447
  • Antonia SJ, Borghaei H, Ramalingam SS, et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol. 2019;20(10):1395–1408.
  • Reck M, Brahmer J, Bennett B, et al. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057. Eur J Cancer. 2018;102:23–30.
  • Bezin J, Duong M, Lassalle R, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(8):954–962.
  • Giaj Levra M, Cotté FE, Corre R, et al. Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: a national data base analysis. Lung Cancer. 2020;140:99–106.
  • Assié JB, Corre R, Levra MG, et al. Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study). Ther Adv Med Oncol. 2020;12:1758835920967237.
  • Chouaïd C, Grumberg V, Batisse A, et al. Machine learning-based analysis of treatment sequences typology in advanced non-small-cell lung cancer long-term survivors treated with nivolumab. JCO Clin Cancer Inform. 2022;6:e2100108.
  • World Health Organization. ICD-10: international statistical classification of diseases and related health problems: tenth revision. 2nd ed. World Health Organization. 2004. https://apps.who.int/iris/handle/10665/42980
  • Heejung B, Tsiatis A, et al. Estimating medical costs with censored data. Biometrika. 2000;87(2):329–343.
  • Pompen M, Gok M, Novák A, et al. Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands. Lung Cancer. 2009;64(1):110–116.
  • Buja A, Rivera M, De Polo A, et al. Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: a whole-disease model. Thorac Cancer. 2021;12(1):13–20.
  • Buja A, Pasello G, De Luca G, et al. Non-small-cell lung cancer: real-world cost consequence analysis. JCO Oncol Pract. 2021;17(8):e1085–e1093.
  • Gadby F, Descourt R, Robinet G, et al. Evolution of the costs and management of lung cancer between 2004 and 2014. Rev Mal Respir. 2020;37(1):1–7.
  • Verleger K, Penrod JR, Manley Daumont M, et al. Costs and cost drivers associated with non-small-cell lung cancer patients who received two or more lines of therapy in Europe. Clinicoecon Outcomes Res. 2020;12:23–33.
  • Bugge C, Saether EM, Brustugun OT, et al. Societal cost of cancer in Norway -results of taking a broader cost perspective. Health Policy. 2021;125(8):1100–1107.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.